Evaluation of digital medical devices: How to take into account the specificities of these solutions?

IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Therapie Pub Date : 2024-01-01 DOI:10.1016/j.therap.2024.01.001
Anouk Trancart , Valery-Pierre Riche , Antoine Disset , Dorothée Camus , Anne Josseran , Pascal Bécache , Cécile Charle-Maachi , Laure De Place , Arthur Denninger , Jérôme Fabiano , Charlotte Gourio , Vincent Vercamer
{"title":"Evaluation of digital medical devices: How to take into account the specificities of these solutions?","authors":"Anouk Trancart ,&nbsp;Valery-Pierre Riche ,&nbsp;Antoine Disset ,&nbsp;Dorothée Camus ,&nbsp;Anne Josseran ,&nbsp;Pascal Bécache ,&nbsp;Cécile Charle-Maachi ,&nbsp;Laure De Place ,&nbsp;Arthur Denninger ,&nbsp;Jérôme Fabiano ,&nbsp;Charlotte Gourio ,&nbsp;Vincent Vercamer","doi":"10.1016/j.therap.2024.01.001","DOIUrl":null,"url":null,"abstract":"<div><p>The beginning of the 21st century has seen an increasing number of digital medical devices (DMDs) arrive on the European market, bringing major benefits and changes for society. DMDs are unique in that they bring intelligence to the organisation of care, and generate and collect a wealth of real-life data with ultra-fast life cycles. They have specific requirements, particularly in terms of data security and interoperability. In France and Europe, the construction of evidence, the assessment process and evaluation methodologies with a view to purchase or reimbursement must adjust to these changes, given the specific features of these technologies. This digital leap has opened up new perspectives for healthcare, along with economic, ethical and regulatory issues. The challenge is to assess the clinical and organisational impact, reliability, safety, interoperability, efficiency and budgetary impact of DMDs in line with the requirements of new standards, guidelines and regulations. This should result in a coherent, pragmatic and proportionate evaluation, so that public decision-makers and buyers can take advantage of the potential opportunities that these digital devices offer to improve healthcare delivery. Thus, a fair and informed evaluation of DMDs would emerge, providing a solid basis to steer their inclusion into contemporary medical practices. This fundamental issue of evaluation, linked to the digital nature of these MDs, is what the round table, comprising experts from academia and/or hospitals, institutions and industry, sought to resolve. Discussions led to proposals on how DMDs should be evaluated, bearing in mind their complexity. The round table set out to identify the bottlenecks in the entire evaluation process, from the CE marking phase, compliance with French safety and interoperability requirements, through to national or local evaluation, in order to inform a purchasing policy and draw up proposals covering the entire spectrum. Ten concrete recommendations were put forward by the round table, aimed at improving the evaluation process by making it clearer and more adaptable, thus offering greater flexibility in the evaluation and decision-making stages. This well-thought-out approach is designed to facilitate a comprehensive and flexible evaluation of DMDs given the constantly evolving technological context.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0040595724000027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The beginning of the 21st century has seen an increasing number of digital medical devices (DMDs) arrive on the European market, bringing major benefits and changes for society. DMDs are unique in that they bring intelligence to the organisation of care, and generate and collect a wealth of real-life data with ultra-fast life cycles. They have specific requirements, particularly in terms of data security and interoperability. In France and Europe, the construction of evidence, the assessment process and evaluation methodologies with a view to purchase or reimbursement must adjust to these changes, given the specific features of these technologies. This digital leap has opened up new perspectives for healthcare, along with economic, ethical and regulatory issues. The challenge is to assess the clinical and organisational impact, reliability, safety, interoperability, efficiency and budgetary impact of DMDs in line with the requirements of new standards, guidelines and regulations. This should result in a coherent, pragmatic and proportionate evaluation, so that public decision-makers and buyers can take advantage of the potential opportunities that these digital devices offer to improve healthcare delivery. Thus, a fair and informed evaluation of DMDs would emerge, providing a solid basis to steer their inclusion into contemporary medical practices. This fundamental issue of evaluation, linked to the digital nature of these MDs, is what the round table, comprising experts from academia and/or hospitals, institutions and industry, sought to resolve. Discussions led to proposals on how DMDs should be evaluated, bearing in mind their complexity. The round table set out to identify the bottlenecks in the entire evaluation process, from the CE marking phase, compliance with French safety and interoperability requirements, through to national or local evaluation, in order to inform a purchasing policy and draw up proposals covering the entire spectrum. Ten concrete recommendations were put forward by the round table, aimed at improving the evaluation process by making it clearer and more adaptable, thus offering greater flexibility in the evaluation and decision-making stages. This well-thought-out approach is designed to facilitate a comprehensive and flexible evaluation of DMDs given the constantly evolving technological context.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
数字医疗设备评估:如何考虑这些解决方案的特殊性?
进入 21 世纪以来,越来越多的数字医疗设备 (DMD) 出现在欧洲市场上,为社会带来了巨大的利益和变化。数字医疗设备的独特之处在于,它们为医疗组织带来了智能,并以超快的生命周期生成和收集大量真实数据。它们有特殊的要求,特别是在数据安全和互操作性方面。在法国和欧洲,鉴于这些技术的特殊性,以购买或报销为目的的证据构建、评估过程和评价方法必须适应这些变化。这一数字飞跃为医疗保健开辟了新的前景,同时也带来了经济、伦理和监管问题。我们面临的挑战是如何根据新标准、指南和法规的要求,评估 DMD 的临床和组织影响、可靠性、安全性、互操作性、效率和预算影响。这应导致连贯、务实和适度的评估,从而使公共决策者和购买者能够利用这些数字设备提供的潜在机会来改善医疗服务。这样,就能对 DMD 进行公平、知情的评估,为将其纳入当代医疗实践提供坚实的基础。由来自学术界和/或医院、机构和行业的专家组成的圆桌会议试图解决的正是与这些 MD 的数字化性质相关的这一基本评估问题。讨论提出了关于如何评估数字化医学博士的建议,同时考虑到其复杂性。圆桌会议旨在找出整个评估过程中的瓶颈,从 CE 标志阶段、符合法国安全和互操作性要求,一直到国家或地方评估,以便为采购政策提供信息,并起草涵盖整个领域的建议。圆桌会议提出了十项具体建议,旨在改进评估程序,使其更加清晰、更具适应性,从而在评估和决策阶段提供更大的灵活性。这种经过深思熟虑的方法旨在促进在不断变化的技术背景下对数字千年发展目标进行全面和灵活的评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapie
Therapie 医学-药学
CiteScore
3.50
自引率
7.70%
发文量
132
审稿时长
57 days
期刊介绍: Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject. The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.
期刊最新文献
Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: A series of 3 cases. Retinal vascular occlusion after COVID-19 vaccination: Analysis of the French pharmacovigilance database. Impact of new drug releases on heart failure management and hospitalizations in France: A repeated cross-sectional study between 2014 and 2023. [Use of a pharmaceutical decision support system in the valuation of hospital stays: Evaluation through 3 examples in collaboration with the department of medical information]. Exposure assessment of titanium dioxide via drugs available on the French market: A nationwide descriptive study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1